Latest ImaginAb Inc. Stories
LOS ANGELES, April 1, 2013 /PRNewswire/ -- ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody technology, today announced that it has changed its name to AmaginAb. During a 'strategy meeting' at a recent employee team-building event, the Company's management belatedly realized that most of the important companies in the biotechnology space begin with the letter 'A'. "It became clear by the third hot chocolate one evening during our...
LOS ANGELES, Oct. 8, 2012 /PRNewswire/ -- ImaginAb, Inc., a clinical-stage company developing in vivo molecular imaging agents based on antibody fragment technology, today announced that it has entered into a collaboration and commercialization agreement with H. Lundbeck A/S. Under the terms of the agreement, ImaginAb and Lundbeck will collaborate around a novel central nervous system (CNS) target in order to explore the use of re-engineered antibodies to accelerate the blood-brain...
LOS ANGELES and ROCKVILLE, Md., Sept. 5, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that it has entered into a collaboration and commercialization agreement with MacroGenics, Inc. Under the terms of the agreement, ImaginAb will develop an anti-CD3 clinical imaging product, for which MacroGenics may receive future milestones and royalties. In addition, ImaginAb will support...
LOS ANGELES and BOSTON, Aug. 13, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that Abbie Celniker, Ph.D. has joined the company as a Director and Chair of the Board. "In ImaginAb's search for Board leadership, we set out to attract an industry visionary with perspective from big biopharma as well as entrepreneurial experience and we have found all of these qualities in Dr....
LOS ANGELES and SINGAPORE, Aug. 7, 2012 /PRNewswire/ -- ImaginAb, Inc. a developer of in vivo molecular imaging agents based on its proprietary antibody fragment platform, today announced that it has signed a Master Service Agreement (MSA) with Singapore Radiopharmaceuticals Pte Ltd, a subsidiary of Fortis HealthCare. "This agreement represents an important component of our expansion program in Singapore as we establish R&D and pre-clinical imaging capabilities there," said...
LOS ANGELES, March 26, 2012 /PRNewswire/ -- ImaginAb, Inc. a clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, today announced the completion of a Series A financing - led by Novartis Venture Funds. The oversubscribed Series A round includes Merieux Developpement, Nextech Invest, Cycad Group and existing seed investor Momentum Biosciences. Novartis Venture Funds and Merieux Developpement will both...
LOS ANGELES, Oct. 31, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce that it has been awarded a total of $2.3 million in funding from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program to help further develop diagnostic imaging agents for Positron Emission Tomography (PET). Over the past 20 years, PET has evolved into a powerful and highly valued tool for the clinical management of cancer but many important areas of oncology still lack...
LOS ANGELES and SINGAPORE, Sept. 6, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce the establishment of a wholly owned Singapore-based subsidiary, ImaginAb Molecular Imaging Pte Ltd (IMI). IMI is the first step in the company's international expansion and marks a significant increase in research capability for the organization. IMI will be established to provide GLP pre-clinical molecular imaging services to both the US parent company and select biopharma partnerships, including...
SAN ANTONIO, June 7, 2011 /PRNewswire/ -- ImaginAb, Inc. is pleased to announce the availability of custom radiolabeling services for proteins, peptides and other macromolecules as of the 1st of July 2011. This is part of the company's ongoing initiative to broaden the range of product and service offerings to the biopharma and research community and is synergistic with existing activities in custom antibody fragment engineering. "Over the past 18 months we have grown our core antibody...
OXFORD, United Kingdom, June 6, 2011 /PRNewswire/ -- Oxford BioMedicaplc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc. ("ImaginAb"), a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the...
